This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jaskowski, T. D. Articles by Hill, H. R. Search for Related Content PubMed PubMed Citation Articles by Jaskowski, T. D. Articles by Hill, H. R.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, June 2006, p. 655-660, Vol. 13, No. 6
1071-412X/06/$08.00+0     doi:10.1128/CVI.00034-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Analysis of Serum Antibodies in Patients Suspected of Having Inflammatory Bowel Disease

Associated Regional and University Pathologists Institute for Clinical and Experimental Pathology,¹ Departments of Pathology,² Pediatrics and Medicine, University of Utah School of Medicine, Salt Lake City, Utah 84108³

Received 27 January 2006/ Returned for modification 2 March 2006/ Accepted 23 March 2006

Inflammatory bowel disease (IBD) is the general term used for a heterogeneous group of intestinal disorders, including Crohn's disease (CD) and ulcerative colitis (UC). Serological markers such as anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophilic cytoplasmic antibody (atypical pANCA) have proven useful in the diagnosis and differentiation of CD and UC. Immunoglobulin A (IgA) antibody directed against the outer membrane protein C (OmpC) of Escherichia coli is said by one group to have clinical utility in diagnosing IBD, specifically in ASCA-negative CD patients. Our objective in this study was to compare the results obtained from two separate laboratories offering similar IBD tests using sera from suspected IBD patients. One hundred ninety-seven sera received for IBD testing were included in the study. The agreement between the two laboratories was 93.4% for ASCA IgA, 90.9% for ASCA IgG, and 87.8% for atypical pANCA IgG. There were 25 sera with ASCA-negative/OmpC-positive results reported by one laboratory. Thirteen of these 25 (52.0%) ASCA-negative/OmpC-positive sera were also atypical pANCA positive (9 as determined by both laboratories, 3 by one, and 1 by the other). Atypical pANCA antibody is found primarily in IBD patients with UC and colon-limited CD (Crohn's colitis). We conclude that the ASCA and atypical pANCA assays showed good agreement between the two laboratories, but the data for ASCA-negative/OmpC-positive sera suggest that many (52.0%) of these patients were more likely to have had UC or Crohn's colitis based on the presence of an atypical pANCA.